Asenapine
Small molecule
Also known as SCH 900274
Evidence outlook
Approved: Schizophrenia, Bipolar Disorder
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (3)
- Acute monotherapy of manic or mixed episodes, in adults and pediatric patients 10 to 17 years of age
- Adjunctive treatment to lithium or valproate in adults
- Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00212784 NCT00212784 · Schizophrenia, Schizoaffective Disorder This 52-week trial randomly assigned 1,225 people with schizophrenia to asenapine or to olanzapine, with participants, carers, investigators and outcome assessors all unaware of assignment. The primary measure was change in total PANSS symptom score. Asenapine improved symptoms by 21.0 points against 27.5 points for olanzapine, a difference favouring olanzapine at p<0.0001, so asenapine was less effective than its active comparator on this measure. Registry: NCT00212784 | 3 | Change in total PANSS score at endpoint (52-week double-blind or last assessment after baseline) from baseline (Screening, Baseline, Week 2, 4, 6, 8, 12, 20, 28, 36, 44, 52 (endpoint)) 2006-03-15 | Change in total PANSS score (52-week active-controlled trial): asenapine -21.0 vs olanzapine -27.5, difference P<0.0001. | Partial signal | link ↗ |
View 1 more trial
ACTAMESA NCT00212771 · Schizophrenia, Schizoaffective Disorder Participants were required to have completed 12 months of treatment in an earlier trial before entering this study, making it a continuation of a prior randomized, blinded, active-controlled schizophrenia trial rather than a fresh standalone comparison. The randomization, quadruple-blinding, and active comparator (olanzapine) are real design strengths, and the primary measure (PANSS change) is a validated clinical outcome, but the external source only reports descriptive mean changes in both arms without any statistical significance test, so it's unclear whether asenapine showed a meaningful advantage over olanzapine. Registry: NCT00212771 | 3 | Change in total PANSS score at endpoint (Screening, Week 76, 100, and once every 24 weeks thereafter until endpoint) 2006-09 | Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (32)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Phase 4 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Dopamine D2 and serotonin 5-HT2A receptors (antagonist) drugs
Clozapine, Iloperidone (Fanapt), Lurasidone, Milsaperidone (VHX-896), Olanzapine (Zyprexa Relprevv) and 17 more. Compare all 23 Dopamine D2 and serotonin 5-HT2A receptors (antagonist) drugs
This mechanism is crowded: 24 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Bipolar Disorder: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Asenapine: this drug | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Aripiprazole (Abilify Maintena) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Aripiprazole (Abilify) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote ER) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | Partial signal | Featured results are non-efficacy only in this race | |
| Iloperidone (Fanapt) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Lamotrigine | Approved | Small molecule | Voltage-gated sodium channel | not yet graded | No reviewed efficacy summary in this indication | |
| Milsaperidone (VHX-896) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Weak signal | No reviewed efficacy summary in this indication | |
| Olanzapine (Zyprexa) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Olanzapine / Samidorphan (Lybalvi) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist) | Reliable signal | No reviewed efficacy summary in this indication | |
| Quetiapine (Seroquel XR) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Quetiapine (Seroquel) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (Risperdal Consta) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (Risperdal) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (Rykindo) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risperidone (Uzedy) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Ziprasidone | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Dexmedetomidine (Igalmi) | Phase 3 | Small molecule | Alpha-2 adrenergic receptor (agonist) | Reliable signal | No reviewed efficacy summary in this indication | |
| Loxapine (Adasuve) | Phase 3 | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | Partial signal | No reviewed efficacy summary in this indication | |
| Xanomeline / Trospium Chloride (Cobenfy) | Phase 3 | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | not yet graded | No reviewed efficacy summary in this indication | |
| ALTO-100 | Phase 2 | Small molecule | First-in-class oral small molecule neural plasticity enhancer | not yet graded | No reviewed efficacy summary in this indication | |
| Brenipatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Elunetirom | Phase 2 | Small molecule | Thyroid hormone receptor-beta | not yet graded | No reviewed efficacy summary in this indication | |
| Icalcaprant | Phase 2 | Small molecule | Kappa-opioid receptor (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| Lithium Salicylate / L-Proline (AL001) | Phase 1/2 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-1042 | Phase 1(overall) | Small molecule | Muscarinic M4 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Aripiprazole (Abilify MyCite) | Discontinued | Combination | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
16 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.